Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Micronised fenofibrate

A Munoz, J P Guichard, P Reginault

    Atherosclerosis
    |October 1, 1994
    PubMed
    Summary
    This summary is machine-generated.

    A new fenofibrate formulation with smaller particle size improves drug absorption and allows for a lower daily dose. This enhanced formulation is expected to provide better control over the absorbed amount and more reproducible therapeutic effects.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Natural history of human immunodeficiency virus type 1 viremia after seroconversion and proximal to AIDS in a large cohort of homosexual men. Multicenter AIDS Cohort Study.

    The Journal of infectious diseases·2000
    Same author

    [Recurrent spontaneous carotid dissection].

    Revista de neurologia·2000
    Same author

    Safety and efficacy of Omniscan (gadodiamide injection) at 0.1 mmol/kg for MRI in infants younger than 6 months of age: phase III open multicenter study.

    Investigative radiology·2000
    Same author

    Percutaneous vertebroplasty: a special syringe for cement injection.

    AJNR. American journal of neuroradiology·2000
    Same author

    OESCLIM: an advanced delivery system for HRT.

    Maturitas·2000
    Same author

    Fenfluramine-induced increase in preproenkephalin mRNA levels in the striatum: interaction between the serotonergic, glutamatergic, and dopaminergic systems.

    Synapse (New York, N.Y.)·2000
    Same journal

    Optimized flow cytometry assay for functional characterization of variants of uncertain significance in familial hypercholesterolemia.

    Atherosclerosis·2026
    Same journal

    Causal insights of modifiable cardiovascular risk factors for dementia risk - potential for efficient prevention and improved brain health.

    Atherosclerosis·2026
    Same journal

    Serial OCT-based coronary physiology and plaque composition in vessels with nonobstructive coronary lesions following intensive lipid-lowering therapy: YELLOW III sub-study.

    Atherosclerosis·2026
    Same journal

    Earliest age to detect lifetime cardiometabolic health stratification in children.

    Atherosclerosis·2026
    Same journal

    Sympathetic neurons exacerbate atherosclerosis by modulating macrophage function via the NPY/Y1R axis.

    Atherosclerosis·2026
    Same journal

    Optimizing lipoprotein(a) testing for immediate clinical impact in primary prevention.

    Atherosclerosis·2026
    See all related articles

    Area of Science:

    • Pharmacology
    • Drug Delivery Systems
    • Physical Pharmacy

    Background:

    • Fenofibrate is a widely used lipid-lowering drug.
    • Current formulations may have variable absorption.
    • Optimizing fenofibrate delivery is crucial for therapeutic efficacy.

    Purpose of the Study:

    • To describe the rationale and development of a novel fenofibrate formulation.
    • To enhance the absorption rate and control of fenofibrate.
    • To improve the reproducibility of fenofibrate's pharmacological and therapeutic outcomes.

    Main Methods:

    • Development of a new fenofibrate formulation.
    • Characterization of particle size distribution.
    • Assessment of drug absorption and bioavailability.

    Related Experiment Videos

  • Evaluation of pharmacological and therapeutic effects.

    • Main Results:

    • The new formulation exhibits a lower dispersion of particle size.
    • This leads to a significantly improved absorption rate of fenofibrate.
    • The optimized absorption allows for a reduced daily dosage.

    Conclusions:

    • The novel fenofibrate formulation offers enhanced absorption and dose control.
    • Improved particle size characteristics are key to its improved performance.
    • This formulation is expected to yield more consistent and reproducible therapeutic results.